{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T10:33:33Z","timestamp":1782556413970,"version":"3.54.5"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,1,26]],"date-time":"2016-01-26T00:00:00Z","timestamp":1453766400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1007\/s13277-016-4870-z","type":"journal-article","created":{"date-parts":[[2016,1,26]],"date-time":"2016-01-26T04:52:57Z","timestamp":1453783977000},"page":"9813-9823","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer"],"prefix":"10.1007","volume":"37","author":[{"given":"Satu","family":"Luhtala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Synn\u00f6ve","family":"Staff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minna","family":"Tanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorma","family":"Isola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,26]]},"reference":[{"key":"4870_CR1","doi-asserted-by":"crossref","first-page":"c3620","DOI":"10.1136\/bmj.c3620","volume":"341","author":"P Autier","year":"2010","unstructured":"Autier P, Boniol M, La Vecchia C, et al. Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database. BMJ. 2010;341:c3620.","journal-title":"BMJ"},{"issue":"6","key":"4870_CR2","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1002\/cncr.27819","volume":"119","author":"AJ Tevaarwerk","year":"2013","unstructured":"Tevaarwerk AJ, Gray RJ, Schneider BP, et al. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years. Cancer. 2013;119(6):1140\u20138.","journal-title":"Cancer"},{"key":"4870_CR3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science. 1987;235:177\u201382.","journal-title":"Science"},{"key":"4870_CR4","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/PAS.0b013e31819437f9","volume":"33","author":"MZ Gilcrease","year":"2009","unstructured":"Gilcrease MZ, Woodward WA, Nicolas MM, et al. Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer. Am J Surg Pathol. 2009;33:759\u201367.","journal-title":"Am J Surg Pathol"},{"key":"4870_CR5","doi-asserted-by":"crossref","first-page":"R37","DOI":"10.1186\/bcr2322","volume":"11","author":"K K\u00f6ninki","year":"2009","unstructured":"K\u00f6ninki K, Tanner M, Auvinen A, et al. HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005. Breast Cancer Res. 2009;11:R37.","journal-title":"Breast Cancer Res"},{"key":"4870_CR6","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1186\/1471-2407-10-539","volume":"10","author":"F Sircoulomb","year":"2010","unstructured":"Sircoulomb F, Bekhouche I, Finetti P, et al. Genome profiling of ERBB2-amplified breast cancers. BMC Cancer. 2010;10:539.","journal-title":"BMC Cancer"},{"key":"4870_CR7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.clbc.2011.03.001","volume":"11","author":"C Palmieri","year":"2011","unstructured":"Palmieri C, Shah D, Krell J, et al. Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era. Clin Breast Cancer. 2011;11:93\u2013102.","journal-title":"Clin Breast Cancer"},{"key":"4870_CR8","first-page":"62","volume":"2","author":"T Vu","year":"2012","unstructured":"Vu T, Claret FX. Trastuzumab: updated mechanisms of action and resistance in breast cancer. Review. Front Oncol. 2012;2:62.","journal-title":"Front Oncol"},{"key":"4870_CR9","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/bjc.1997.550","volume":"76","author":"KA Scott","year":"1997","unstructured":"Scott KA, Walker RA. Lack of cyclin E immunoreactivity in non-malignant breast and association with proliferation in breast cancer. Br J Cancer. 1997;76:1288\u201392.","journal-title":"Br J Cancer"},{"key":"4870_CR10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10330-005-0371-z","volume":"5","author":"W He","year":"2006","unstructured":"He W, Huang T, Wang H. Expression of cyclin E and its relationship with the prognosis of patients with breast cancer. Chin-Ger J Clin Oncol. 2006;5:275\u20138.","journal-title":"Chin-Ger J Clin Oncol"},{"key":"4870_CR11","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1073\/pnas.1014835108","volume":"108","author":"M Scaltriti","year":"2011","unstructured":"Scaltriti M, Eichhorn PJ, Cort\u00e9s J, et al. Cyclin E amplification\/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci U S A. 2011;108:3761\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4870_CR12","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/bcr3154","volume":"14","author":"R Natrajan","year":"2012","unstructured":"Natrajan R, Mackay A, Wilkerson PM, Lambros MB, Wetterskog D, Arnedos M, et al. Functional characterization of the 19q12 amplicon in grade III breast cancers. Breast Cancer Res. 2012;14:R53.","journal-title":"Breast Cancer Res"},{"key":"4870_CR13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.semcdb.2005.02.007","volume":"16","author":"I S\u00e1nchez","year":"2005","unstructured":"S\u00e1nchez I, Dynlacht BD. New insights into cyclins, CDKs, and cell cycle control. Review. Semin Cell Dev Biol. 2005;16:311\u201321.","journal-title":"Semin Cell Dev Biol"},{"issue":"5","key":"4870_CR14","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1128\/MCB.15.5.2612","volume":"15","author":"M Ohtsubo","year":"1995","unstructured":"Ohtsubo M, Theodoras AM, Schumacher J, et al. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol. 1995;15(5):2612\u201324.","journal-title":"Mol Cell Biol"},{"issue":"7","key":"4870_CR15","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1128\/MCB.15.7.3463","volume":"15","author":"D Resnitzky","year":"1995","unstructured":"Resnitzky D, Reed SI. Different roles for cyclins D1 and E in regulation of the G1-to-S transition. Mol Cell Biol. 1995;15(7):3463\u20139.","journal-title":"Mol Cell Biol"},{"key":"4870_CR16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1053\/hupa.2001.21141","volume":"32","author":"R Donnellan","year":"2001","unstructured":"Donnellan R, Kleinschmidt I, Chetty R. Cyclin E immunoexpression in breast ductal carcinoma: pathologic correlations and prognostic implications. Hum Pathol. 2001;32:89\u201394.","journal-title":"Hum Pathol"},{"key":"4870_CR17","first-page":"59","volume":"25","author":"P Potemski","year":"2006","unstructured":"Potemski P, Kusinska R, Watala C, et al. Cyclin E expression in breast cancer correlates with negative steroid receptor status, HER2 expression, tumor grade and proliferation. J Exp Clin Cancer Res. 2006;25:59\u201364.","journal-title":"J Exp Clin Cancer Res"},{"key":"4870_CR18","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1080\/07357900600894799","volume":"24","author":"L Wang","year":"2006","unstructured":"Wang L, Shao ZM. Cyclin E expression and prognosis in breast cancer patients: a meta-analysis of published studies. Cancer Investig. 2006;24:581\u20137.","journal-title":"Cancer Investig"},{"key":"4870_CR19","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1007\/s13277-013-0915-8","volume":"34","author":"S Gao","year":"2013","unstructured":"Gao S, Ma JJ, Lu C. Prognostic value of cyclin E expression in breast cancer: a meta-analysis. Tumor Biol. 2013;34:3423\u201330.","journal-title":"Tumor Biol"},{"key":"4870_CR20","doi-asserted-by":"crossref","first-page":"6573","DOI":"10.1038\/sj.onc.1205847","volume":"21","author":"JF Timms","year":"2002","unstructured":"Timms JF, White SL, O\u2019Hare MJ, et al. Effects of ErbB-2 overexpression on mitogenic signalling and cell cycle progression in human breast luminal epithelial cells. Oncogene. 2002;21:6573\u201386.","journal-title":"Oncogene"},{"key":"4870_CR21","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1038\/onc.2010.151","volume":"29","author":"EA Mittendorf","year":"2010","unstructured":"Mittendorf EA, Liu Y, Tucker SL, et al. A novel interaction between HER2\/neu and cyclin E in breast cancer. Oncogene. 2010;29:3896\u2013907.","journal-title":"Oncogene"},{"key":"4870_CR22","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa053028","volume":"354","author":"H Joensuu","year":"2006","unstructured":"Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354:809\u201320.","journal-title":"N Engl J Med"},{"key":"4870_CR23","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/jjco\/hyi246","volume":"36","author":"P Potemski","year":"2006","unstructured":"Potemski P, Pluciennik E, Bednarek AK, et al. Cyclin E expression in operable breast cancer quantified using real-time RT-PCR: a comparative study with immunostaining. Jpn J Clin Oncol. 2006;36:142\u20139.","journal-title":"Jpn J Clin Oncol"},{"key":"4870_CR24","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/modpathol.3880432","volume":"14","author":"M Olvera","year":"2001","unstructured":"Olvera M, Harris S, Amezcua CA, et al. Immunohistochemical expression of cell cycle proteins E2F-1, Cdk-2, Cyclin E, p27(kip1), and Ki-67 in normal placenta and gestational trophoblastic disease. Mod Pathol. 2001;14:1036\u201342.","journal-title":"Mod Pathol"},{"key":"4870_CR25","doi-asserted-by":"crossref","first-page":"R56","DOI":"10.1186\/bcr2615","volume":"12","author":"VJ Tuominen","year":"2010","unstructured":"Tuominen VJ, Ruotoistenm\u00e4ki S, Viitanen A, et al. ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res. 2010;12:R56.","journal-title":"Breast Cancer Res"},{"key":"4870_CR26","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1073\/pnas.90.3.1112","volume":"90","author":"K Keyomarsi","year":"1993","unstructured":"Keyomarsi K, Pardee AB. Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci U S A. 1993;90:1112\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"4870_CR27","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1158\/1535-7163.1585.3.12","volume":"3","author":"M Tanner","year":"2004","unstructured":"Tanner M, Kapanen AI, Junttila T, et al. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther. 2004;3(12):1585\u201392.","journal-title":"Mol Cancer Ther"},{"key":"4870_CR28","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1756-0500-2-140","volume":"2","author":"P Bostr\u00f6m","year":"2009","unstructured":"Bostr\u00f6m P, S\u00f6derstr\u00f6m M, Palokangas T, et al. Analysis of cyclins A, B1, D1 and E in breast cancer in relation to tumour grade and other prognostic factors. BMC Res Notes. 2009;2:140.","journal-title":"BMC Res Notes"},{"issue":"5","key":"4870_CR29","first-page":"941","volume":"11","author":"K Keyomarsi","year":"1995","unstructured":"Keyomarsi K, Conte Jr D, Toyofuku W, et al. Deregulation of cyclin E in breast cancer. Oncogene. 1995;11(5):941\u201350.","journal-title":"Oncogene"},{"key":"4870_CR30","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/jso.10268","volume":"83","author":"S Han","year":"2003","unstructured":"Han S, Park K, Bae BN, et al. Prognostic implication of cyclin E expression and its relationship with cyclin D1 and p27Kip1 expression on tissue microarrays of node negative breast cancer. J Surg Oncol. 2003;83:241\u20137.","journal-title":"J Surg Oncol"},{"key":"4870_CR31","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/ejso.2001.1137","volume":"27","author":"HK Kim","year":"2001","unstructured":"Kim HK, Park IA, Heo DS, et al. Cyclin E overexpression as an independent risk factor of visceral relapse in breast cancer. Eur J Surg Oncol. 2001;27:464\u201371.","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"4870_CR32","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/modpathol.2010.84","volume":"23","author":"CB Moelans","year":"2010","unstructured":"Moelans CB, de Weger RA, Monsuur HN, et al. Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes. Mod Pathol. 2010;23(7):1029\u201339.","journal-title":"Mod Pathol"},{"key":"4870_CR33","doi-asserted-by":"crossref","first-page":"38ra47","DOI":"10.1126\/scitranslmed.3000611","volume":"2","author":"HG Russnes","year":"2010","unstructured":"Russnes HG, Vollan HK, Lingjaerde OC, et al. Genomic architecture characterizes tumor progression paths and fate in breast cancer patients. Sci Transl Med. 2010;2:38ra47.","journal-title":"Sci Transl Med"},{"issue":"3","key":"4870_CR34","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/path.1694","volume":"205","author":"G Callagy","year":"2005","unstructured":"Callagy G, Pharoah P, Chin SF, et al. Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays. J Pathol. 2005;205(3):388\u201396.","journal-title":"J Pathol"},{"key":"4870_CR35","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/carcin\/bgh019","volume":"25","author":"T Lindahl","year":"2004","unstructured":"Lindahl T, Landberg G, Ahlgren J, et al. Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer. Carcinogenesis. 2004;25:375\u201380.","journal-title":"Carcinogenesis"},{"key":"4870_CR36","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/ijc.1311","volume":"93","author":"IR Bukholm","year":"2001","unstructured":"Bukholm IR, Bukholm G, Nesland JM. Over-expression of cyclin A is highly associated with early relapse and reduced survival in patients with primary breast carcinomas. Int J Cancer. 2001;93:283\u20137.","journal-title":"Int J Cancer"},{"key":"4870_CR37","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1477-7819-9-31","volume":"9","author":"K Pillay","year":"2011","unstructured":"Pillay K, McCleod H, Chetty R, et al. A study to investigate the role of p27 and cyclin E immunoexpression as a prognostic factor in early breast carcinoma. World J Surg Oncol. 2011;9:31.","journal-title":"World J Surg Oncol"},{"issue":"5","key":"4870_CR38","first-page":"1143","volume":"12","author":"MG Peters","year":"2004","unstructured":"Peters MG, Vidal Mdel C, Gim\u00e9nez L, et al. Prognostic value of cell cycle regulator molecules in surgically resected stage I and II breast cancer. Oncol Rep. 2004;12(5):1143\u201350.","journal-title":"Oncol Rep"},{"issue":"21","key":"4870_CR39","doi-asserted-by":"crossref","first-page":"9727","DOI":"10.1158\/0008-5472.CAN-04-3984","volume":"65","author":"P Berglund","year":"2005","unstructured":"Berglund P, Stighall M, Jirstr\u00f6m K, et al. Cyclin E overexpression obstructs infiltrative behavior in breast cancer: a novel role reflected in the growth pattern of medullary breast cancers. Cancer Res. 2005;65(21):9727\u201334.","journal-title":"Cancer Res"},{"issue":"4","key":"4870_CR40","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/path.1322","volume":"199","author":"H K\u00fchling","year":"2003","unstructured":"K\u00fchling H, Alm P, Olsson H, et al. Expression of cyclins E, A, and B, and prognosis in lymph node-negative breast cancer. J Pathol. 2003;199(4):424\u201331.","journal-title":"J Pathol"},{"issue":"11 Pt 1","key":"4870_CR41","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1158\/1078-0432.CCR-06-0225","volume":"12","author":"AM Sieuwerts","year":"2006","unstructured":"Sieuwerts AM, Look MP, Meijer-van Gelder ME, et al. Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients. Clin Cancer Res. 2006;12(11 Pt 1):3319\u201328.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4870_CR42","first-page":"MT34","volume":"15","author":"P Potemski","year":"2009","unstructured":"Potemski P, Kusi\u0144ska R, Pasz-Walczak G, et al. Prognostic relevance of cyclin E expression in operable breast cancer. Med Sci Monit. 2009;15(2):MT34\u201340.","journal-title":"Med Sci Monit"},{"key":"4870_CR43","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1245\/s10434-011-2032-5","volume":"19","author":"SP Bagaria","year":"2012","unstructured":"Bagaria SP, Ray PS, Wang J, et al. Prognostic value of basal phenotype in HER2-overexpressing breast cancer. Ann Surg Oncol. 2012;19:935\u201340.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"4870_CR44","doi-asserted-by":"crossref","first-page":"R129","DOI":"10.1186\/bcr3324","volume":"14","author":"I Vaz-Luis","year":"2012","unstructured":"Vaz-Luis I, Ottesen RA, Hughes ME, et al. Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Breast Cancer Res. 2012;14(5):R129.","journal-title":"Breast Cancer Res"},{"key":"4870_CR45","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1056\/NEJMoa021153","volume":"347","author":"K Keyomarsi","year":"2002","unstructured":"Keyomarsi K, Tucker SL, Buchholz TA, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med. 2002;347:1566\u201375.","journal-title":"N Engl J Med"},{"key":"4870_CR46","first-page":"481","volume":"60","author":"RM Harwell","year":"2000","unstructured":"Harwell RM, Porter DC, Danes C, et al. Processing of cyclin E differs between normal and tumor breast cells. Cancer Res. 2000;60:481\u20139.","journal-title":"Cancer Res"},{"key":"4870_CR47","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.4161\/cc.8.7.8119","volume":"8","author":"H Wingate","year":"2009","unstructured":"Wingate H, Puskas A, Duong M, et al. Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression. Cell Cycle. 2009;8:1062\u20138.","journal-title":"Cell Cycle"},{"key":"4870_CR48","doi-asserted-by":"crossref","first-page":"6254","DOI":"10.1128\/MCB.21.18.6254-6269.2001","volume":"21","author":"DC Porter","year":"2001","unstructured":"Porter DC, Zhang N, Danes C, et al. Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms. Mol Cell Biol. 2001;21:6254\u201369.","journal-title":"Mol Cell Biol"},{"key":"4870_CR49","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1158\/0008-5472.CAN-09-4094","volume":"70","author":"R Bagheri-Yarmand","year":"2010","unstructured":"Bagheri-Yarmand R, Biernacka A, Hunt KK, et al. Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification. Cancer Res. 2010;70:5074\u201384.","journal-title":"Cancer Res"},{"key":"4870_CR50","doi-asserted-by":"crossref","first-page":"245","DOI":"10.9738\/1400.1","volume":"96","author":"Y Tokai","year":"2011","unstructured":"Tokai Y, Maeda S, Yamaguchi J, et al. Cyclin E low-molecular-weight isoform as a predictor of breast cancer in Japanese women. Int Surg. 2011;96:245\u201353.","journal-title":"Int Surg"},{"key":"4870_CR51","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1158\/0008-5472.CAN-08-4182","volume":"69","author":"NA Delk","year":"2009","unstructured":"Delk NA, Hunt KK, Keyomarsi K. Altered subcellular localization of tumor-specific cyclin E isoforms affects cyclin-dependent kinase 2 complex formation and proteasomal regulation. Cancer Res. 2009;69:2817\u201325.","journal-title":"Cancer Res"}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-016-4870-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13277-016-4870-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-016-4870-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T16:29:02Z","timestamp":1692203342000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-016-4870-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,26]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["4870"],"URL":"https:\/\/doi.org\/10.1007\/s13277-016-4870-z","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,26]]}}}